The Latest Headlines at American Banking and Market News
Contrasting EF Hutton Acquisition Co. I (NASDAQ:EFHT) and Morgan Stanley Direct Lending (NYSE:MSDL)
EF Hutton Acquisition Co. I (NASDAQ:EFHT – Get Free Report) and Morgan Stanley Direct Lending (NYSE:MSDL – Get Free Report) are both small-cap unclassified companies, but which is the superior business? We will compare... More of this article »
Genius Sports (NYSE:GENI) Receives “Buy” Rating from Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Genius Sports (NYSE:GENI – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a $9.00 price... More of this article »
Needham & Company LLC Reiterates Buy Rating for Personalis (NASDAQ:PSNL)
Needham & Company LLC reissued their buy rating on shares of Personalis (NASDAQ:PSNL – Free Report) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $3.50 price objective... More of this article »
Paragon 28 (NYSE:FNA) PT Lowered to $14.00
Paragon 28 (NYSE:FNA – Free Report) had its price objective reduced by Needham & Company LLC from $17.00 to $14.00 in a research note published on Thursday, Benzinga reports. They currently have a buy rating on the stock. Several... More of this article »
HC Wainwright Reaffirms Buy Rating for Fuel Tech (NASDAQ:FTEK)
HC Wainwright reaffirmed their buy rating on shares of Fuel Tech (NASDAQ:FTEK – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a $4.00 target price on the industrial... More of this article »
Hecla Mining (NYSE:HL) Earns “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Hecla Mining (NYSE:HL – Free Report) in a report released on Thursday, Benzinga reports. They currently have a $10.25 target price on the basic materials company’s... More of this article »
Mirum Pharmaceuticals’ (MIRM) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright restated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) in a report issued on Thursday morning, Benzinga reports. They currently have a $58.00 price objective on the stock. MIRM... More of this article »
Griffon (NYSE:GFF) Price Target Raised to $86.00 at Robert W. Baird
Griffon (NYSE:GFF – Free Report) had its price target lifted by Robert W. Baird from $84.00 to $86.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have an outperform rating on the conglomerate’s... More of this article »
Needham & Company LLC Reiterates Hold Rating for LivePerson (NASDAQ:LPSN)
Needham & Company LLC restated their hold rating on shares of LivePerson (NASDAQ:LPSN – Free Report) in a research report released on Thursday morning, Benzinga reports. LPSN has been the subject of a number of other research... More of this article »
Vaxcyte (NASDAQ:PCVX) Stock Rating Reaffirmed by Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Vaxcyte (NASDAQ:PCVX – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a $95.00 target price... More of this article »
Needham & Company LLC Reiterates “Buy” Rating for Revolution Medicines (NASDAQ:RVMD)
Needham & Company LLC reiterated their buy rating on shares of Revolution Medicines (NASDAQ:RVMD – Free Report) in a research report released on Thursday, Benzinga reports. Needham & Company LLC currently has a $46.00... More of this article »
Robert W. Baird Cuts Emerson Electric (NYSE:EMR) Price Target to $116.00
Emerson Electric (NYSE:EMR – Free Report) had its price objective reduced by Robert W. Baird from $120.00 to $116.00 in a report released on Thursday morning, Benzinga reports. They currently have a neutral rating on the industrial... More of this article »
Middlesex Water (NASDAQ:MSEX) PT Raised to $58.00 at Robert W. Baird
Middlesex Water (NASDAQ:MSEX – Free Report) had its price target hoisted by Robert W. Baird from $56.00 to $58.00 in a research note published on Thursday, Benzinga reports. Robert W. Baird currently has an outperform rating... More of this article »